Consumer Defensive
Rohto Pharmaceutical Co.,Ltd.(RPHCF)
Live Price
Offline$15.00
+0.00% today
1Y Change
+1.90%
Window
Jun 23, 2025 → Jun 16, 2026
- Market Cap
- $532.71B
- Revenue Growth
- +14.0%
- EPS Growth
- +0.4%
- Dividend Yield
- 1.9%
Coverage: 254 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rohto Pharmaceutical Co.,Ltd. (RPHCF) is a Consumer Defensive stock with a market cap of $532.71B and listed on OTC. The stock last traded around $15.00 and up 1.9% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +14.0%, EPS growth of +0.4%, a dividend yield of 1.9%. What stands out right now is revenue +14.0%, EPS +0.4%, free cash flow +4.0% with operating margin 11.8% and ROIC 7.9%. The dividend is present but secondary, with a yield around 1.9%. Valuation is more restrained than many high-expectation growth names at P/E 15.5 and price/sales 1.6. Stock Foundry combines RPHCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Defensive peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+14.0% vs +1.7% peer median
Operating Margin
Above sector median
+11.8% vs +6.6% peer median
P/E
Near sector median
15.5 vs 14.0 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +14.0% and EPS at +0.4%, with operating margin around 11.8%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.9%, which matters if the thesis depends on income as much as growth.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RPHCF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RPHCF Max Drawdown
-12.02%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RPHCF and SPY.
Company Overview
Rohto Pharmaceutical Co.,Ltd.
Other OTC
Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin; medicine for internal use, such as digestive and herbal medicines; oral medicines comprising gastrointestinal medicines, herbal medicines, and supplements; non-prescription medicines; and beauty counters that provide beauty and health services. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co.,Ltd. in September 1949. Rohto Pharmaceutical Co.,Ltd. was founded in 1899 and is headquartered in Osaka, Japan.
- Leadership
- Hidetoshi Segi
- IPO Date
- Mar 10, 2010
- Employees
- 7.3k
- Street Address
- 1-8-1, Tatsumi-nishi
- Mailing
- Osaka, 544-8666
- Region
- Osaka, JP
- Reporting Currency
- USD
- Investor Line
- 81 6 6758 1231
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 15.5
- EV/EBITDA
- 8.9
- Price/Sales
- 1.6
- Price/Book
- 1.9
Growth
- Revenue
- +14.0%
- EPS
- +0.4%
- Free Cash Flow
- +4.0%
Profitability
- Gross Margin
- 55.4%
- Operating Margin
- 11.8%
- Net Margin
- 10.3%
- ROE
- 12.7%
- ROIC
- 7.9%
Balance Sheet
- Debt/Equity
- 0.18
- Current Ratio
- 2.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.